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Background: Neonates routinely receive vitamin K to prevent vitamin K deficiency bleeding, which is associated
with a high mortality rate and a high frequency of neurological sequelae. A coagulation screening test might be
necessary to detect prophylactic failure or incomplete prophylaxis. However, venous access and the volume of blood
required for such testing can be problematic. CoaguChek XS is a portable device designed to monitor prothrombin
time while only drawing a small volume of blood. Although the device is used in adults and children, studies have not
been performed to evaluate its clinical utility in neonates, and the reference value is unknown in this population. The
objectives of the present study were to determine the reference intervals (RIs) for international normalized ratio (INR)
using the CoaguChek XS by capillary puncture in healthy term neonates, to evaluate factors that correlate with INR,
and to evaluate the device by assessing its ease of use in clinical practice.
Methods: This study included 488 healthy term neonates born at a perinatal center between July 2012 and June 2013.
The INRs determined by CoaguChek XS were measured in 4-day-old neonates.
Results: The enrolled neonates were orally administered vitamin K 6-12 h after birth. A RI for INRs in 4-day-old neonates
was established using the CoaguChek XS with a median value of 1.10 and a range of 0.90–1.30. A significant difference
in the INR was noted between male (median value, 1.10; RI, 0.90–1.30) and female (median value, 1.10; RI, 0.90–1.24)
neonates (p = 0.049). The INR was found to correlate with gestational age, birth weight, and hematocrit value.
Conclusions: The CoaguChek XS device is safe, fast, and convenient for performing INR assays in neonates. Our study
is the first to establish a RI for INRs that were measured using the CoaguChek XS in healthy term neonates.
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Neonatal vitamin K deficiency bleeding (VKDB) causes
digestive tract bleeding in the early neonatal period and
intracranial hemorrhage in early infancy. The incidence
of VKDB in infants without prophylaxis has been reported
to range from 4.4 to 10.5 per 100,000 live births in Asia
and Europe [1]. In Japan, a nation-wide survey in 1981,
before vitamin K prophylaxis was recommended, revealed
that 7.1 cases of VKDB occurred per 100,000 births. In
1988, to prevent this condition, a protocol of three oral
doses of vitamin K, 2 mg each, was recommended for
all full-term neonates; these are given on the day of
birth, upon discharge from the maternity hospital, and
at 1 month of age. With the incorporation of these* Correspondence: sige_pd@yahoo.co.jp
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unless otherwise stated.prophylaxis guidelines, the frequency of VKDB in Japan
has significantly decreased. In a nation-wide survey in
2005, the incidence of VKDB was determined to be 1.9
per 100,000 births [2]. However, prophylactic failure
has continued to occur in infants who were later proven
to have cholestatic liver disease, although other main
risk factors include parental refusal and accidental
omission [3,4]. In addition, oral vitamin K prophylaxis
is considered incomplete if at least one oral dose but
not all recommended doses are given according to age,
or if an inadequate dose or preparation is given, although
it is considered complete if all recommended doses are
given at the time of bleeding. According to the latest
nationwide survey in Japan, 89% of infants with VKDB
had received prophylactic vitamin K at least once during
or after the neonatal period [2]. In the current system,
prophylactic failures or incomplete prophylaxis cannot betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Iijima et al. BMC Pediatrics 2014, 14:179 Page 2 of 6
http://www.biomedcentral.com/1471-2431/14/179identified before bleeding occurs. Therefore, a coagulation
screening test, which is a reliable method to detect
prophylactic failures or incomplete prophylaxis, might
be warranted. In neonates, however, two major difficulties
arise when taking blood samples for coagulation tests:
the challenge of venous access and the comparatively
large amount of blood required.
Portable point-of-care (POC) analytical instruments for
measurement of capillary whole blood prothrombin time
(PT), which is expressed by the international normalized
ratio (INR), have been available for the last decade, and
the system offers convenient and accurate anticoagulant
monitoring in adult patients [5]. Using this method can
reduce the volume of blood needed for tests, and capillary
blood samples from heel pricks may provide a solution
to difficult venous access. To date, however, only a few
studies evaluating such portable coagulometers have been
conducted in children [6-8], and no studies in neonates.
The main objectives of the present study were to estab-
lish reference intervals (RIs) of POC capillary puncture
INR for a coagulation screening test in healthy term
neonates and to evaluate factors that correlate with INR.
In addition, we evaluated the validity and utility of the
CoaguChek XS device in neonates.
Methods
Patients and data collection
The subjects were healthy neonates born at Hamamatsu
University Hospital from July 1, 2012 to June 30, 2013.
They were born at full term (37–41 weeks of gestation)
with normal birth weight (2500–3999 g), and all of them
were given 2 mg of vitamin K syrup (Menatetrenone
Kaytwo Syrup, Eisai Co., Ltd., Tokyo, Japan) orally 6–12 h
after birth. Our intention was to evaluate the RI of INR
in healthy term neonates and, therefore, all neonates
hospitalized in the neonatal intensive care unit (NICU)
were excluded from this portion of the study. After
informed consent was obtained from the parents, neo-
nates were enrolled prospectively in this study.
A capillary whole blood sample was obtained by heel
prick at the same time of a blood sampling for the
screening of inherited metabolic disorders (mass-screen-
ing) and the routine serum bilirubin and hematocrit
measurement when the babies had a health checkup at
4 days after birth. The coagulation screening test consisted
of PT using a portable coagulometer, CoaguChek XS, and
the INR was calculated. A single heel prick was performed
and the first drop of capillary blood (at least 8 μL)
obtained was then applied to the test strip, which was
already inserted into the CoaguChek XS device. Next, a
whole blood sample (approximately 40 μL) was collected
into a heparinized capillary tube for measurement of
serum bilirubin and hematocrit values. Finally, another
whole blood sample (at most 200 μL) for mass-screeningwas collected on the filter paper. Blood samples were
drawn by four dedicated and experienced NICU doctors
who had received training in the use of the CoaguChek
XS. The serum bilirubin level was measured by the
optical density method using Bilmeter F (Mochida-Siemens,
Tokyo, Japan). Hematocrit was measured by the microhe-
matocrit method. This study was reviewed and approved
by the Hamamatsu University School of Medicine Ethics
Committee.
Portable coagulometer
CoaguChek XS is a small, battery-powered, handheld
meter that is portable and efficient. It measures the INR
using whole blood obtained by capillary puncture. The
procedure involves insertion of a test strip into the
monitor and application of a drop of blood (8 μL) onto
the test strip. The monitor uses an electrochemical method
to determine the PT after activation of coagulation with
a recombinant human thromboplastin within the test
strip. The mean international sensitivity index (ISI) for the
CoaguChek XS PT test is 1.01. The PT is then converted
to an INR using the ISI that was previously determined
and encoded on the chip for each lot of test strips. The
INR result is usually provided in less than 1 minute
(approximately 10 seconds after application of blood to
the test strip).
Assessment of utility
Instances in which a PT result could not be obtained were
recorded and the failure rate of the method was calcu-
lated. In addition, the doctors were asked questions about
the utility and ease of use of the CoaguChek XS system.
Determination of accuracy
Using linear regression analysis, the accuracy of Coagu-
Chek XS was assessed by comparing INRs obtained using
this method to those measured using the laboratory gold
standard method in neonates who were admitted to the
NICU over the same period. The patients underwent a
coagulation study including determination of INR accord-
ing to their clinical indications, for example, pre-and
postoperative major surgery and other causes of bleeding.
Blood samples were collected from arterial catheters or by
direct venipuncture. Whole blood was drawn first into a
2.5-mL plastic syringe without any anticoagulant. The first
drop of blood was immediately applied to the test strip to
obtain the CoaguChek INR. Subsequently, 1.8 mL of
blood was dispensed and mixed in a collection tube con-
taining sodium citrate for assessing the laboratory INR.
Statistical analysis
Results are expressed as mean (±standard deviation: SD)
for normally distributed continuous variables and median
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and percentages. Statistical methods recommended by the
CLSI C28-A3 document were used to define the RIs [9].
Normality was evaluated by histograms for the variable
and the one-sample Shapiro-Wilk test. The presence of
outliers was determined using Dixon’s test [9]. The RIs for
INR were defined by nonparametric 95th percentile inter-
vals [9]. Correlation between variables was evaluated by
Spearman’s correlation coefficient. The Mann-Whitney U
test and the Kruskal-Wallis test or chi-square test were
used as appropriate. Simple and multivariate regression
analyses were employed to evaluate the influence of
gender, gestational age, birth weight, nutrition, serum
bilirubin and hematocrit value on INR. The Statistical
Package for Social Sciences (SPSS version 18, Tokyo,
Japan) for Windows was used to manage and analyze
the data. A P-value of less than 0.05 was considered to
be statistically significant.INR
0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
Figure 1 Histogram of international normalized ratios (INRs)
measured by CoaguChek XS in 488 healthy term neonates.Results
INR reference intervals
This study included 498 healthy term neonates. INR values
were measurable in 488 out of all of the enrolled neonates.
The sample size was in accordance with the rigorous
CLSI guidelines for determining laboratory RIs, which
recommend a minimum of 120 subjects for determination
of a 95th percentile clinical reference range [9]. Demo-
graphic characteristics and laboratory findings of the study
population are shown in Table 1. There were no outliers
in the INR data. The histogram of INRs of 488 healthy
term neonates is shown in Figure 1. It seemed to show an
approximately normal distribution, but the Shapiro-Wilk
test did not indicate that the distribution of INRs was
normal. Accordingly, a non-parametric approach was
employed to construct the RIs of INRs. As a result, the
median INR was 1.10, and the reference interval (RI)
expressed by the 95th percentile interval was between
0.90 and 1.30. A substantial discrepancy existed between
the INRs of male and female neonates (p = 0.049), and the
gender-specific RIs are shown in Table 2.Table 1 Demographic data of the study population by gende
Total
n 488
Gestational age , wks 39.4 (38.6-40.2)
Birth weight, g 3050 (2806-3294)
Vaginal delivery, n (%) 395 (81)
Breastfeeding only, n (%) 311 (64)
Serum total bilirubin level, mg/dL 11.3 ± 2.8
Hemotocrit level, % 52.0 ± 5.8
Values are presented as median (interquartile rang) or mean ± standard deviation (SCorrelation factors
To analyze the influences of the demographic charac-
teristics and laboratory findings on INR, simple linear
regression was performed with INR as the dependent
variable, and gestational age, birth weight, mode of deliv-
ery, nutrition, serum total bilirubin value and hematocrit
value as independent variables. We observed negative
correlations between INR and gestational age (r = -0.17,
p < 0.001) and birth weight (r = -0.20, p < 0.001). INR was
significantly correlated with hematocrit value (r = 0.37,
p < 0.001) and serum bilirubin value (r = 0.15, p = 0.001).
As for the other independent variables, there was no
significant correlation between INR and each variable.
Next, multiple linear regression was performed in order
to clarify the influence of the independent variables on
the INR. We thought that this analysis is reliable becauser
Male Female
243 245
39.4 (38.6-40.3) 39.4 (38.6-40.3)
3096 (2844-3348) 3000 (2753-3247)
201 (83) 194 (79)
162 (67) 149 (61)
11.7 ± 2.9 11.0 ± 2.8
52.0 ± 6.0 52.1 ± 5.6
D) unless otherwise indicated.
Table 2 Reference intervals of INRs in healthy term
neonates
Gender n Median 2.5th percentile 97.5th percentile
All 488 1.10 0.90 1.30
Male 243 1.10 0.90 1.30
Female 245 1.10 0.90 1.24
INRs, international normalized ratios.
Figure 2 Relationship between INR values obtained by CoaguChek
XS and INR values measured in the laboratory. n = 18, r = 0.967,
p < 0.001.
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were not normally distributed in the Shapiro-Wilk test. As
a result, gender significantly influenced the INR value.
Inverse correlations were observed between INR and
gestational age and birth weight. Conversely, there was
a significant positive correlation between INR and hema-
tocrit value. The other independent variables including
serum bilirubin value had no significant correlation with
INR. The regression coefficients in the multiple linear
regression model are shown in Table 3.
CoaguChek XS utility
There were 10 failures (failure rate 2%). Failures seemed
to be independent of neonate characteristics. In all
instances, an INR result could not be obtained due to
insufficient sample volume, because the neonate strug-
gled when his heel was pricked and the blood could not
be applied to the test strip correctly.
Accuracy of CoaguChek XS
During the study period, arterial or venous blood samples
of 18 patients admitted to the NICU (median gestational
age, 38.1 weeks; median birth weight, 2829 g; median age
at blood sampling, 3 days after birth) were taken to deter-
mine INR values using the CoaguChek XS and those in
the central laboratory as the reference method. Figure 2
illustrates the correlation between INRs obtained using
the CoaguChek XS and the laboratory method. The over-
all Spearman correlation coefficient was 0.967 (p < 0.001).
In addition, individual differences between laboratory INR
and CoaguChek INR values were less than 0.1 in 11 cases
(61%) and less than 0.15 in 17 cases (94%). These resultsTable 3 Multiple linear regression model showing the
association of INR with predictors
Factor Regression coefficient P value
Male gender 0.111 0.006
Gestational age -0.170 <0.001
Birth weight -0.147 0.001
Vaginal delivery 0.055 0.203
Breastfeeding only 0.006 0.883
Serum total bilirubin level 0.010 0.814
Hematocrit level 0.387 <0.001
INR, international normalized ratio.demonstrate the CoaguChek XS meter to be accurate for
use in neonates.
Discussion
There has been no previous study on INR in healthy
full-term neonates as measured by CoaguChek XS. We
successfully established the RIs of CoaguChek INR in
this population. According to the manufacturer’s report,
the normal range for an INR done with a CoaguChek
XS is between 0.9 and 1.1. The RI for INR in neonates
in our study was not so different from that in adults. It
is known that classic PT is high on the first and second
days of life but normalizes by the fifth day [10]. Oral
vitamin K administration after birth might contribute to
the result.
There was a statistically significant difference in INR
values between male and female neonates, with the male
group having a significantly higher INR value. Some previ-
ous studies reported a trend toward enhanced coagulation
in females compared with males; females have a higher
rate of fibrin formation, and increased levels of fibrinogen,
factor VII, factor VIII, and factor IX and a decreased level
of protein C are associated with increased coagulation
activation [11,12]. However, these studies were conducted
in an adult population. There has been no study investi-
gating gender differences in neonatal coagulation. In
our study, the RIs were close between male and female
neonates, although they were statistically significant;
the gender difference might be irrelevant to detecting
prophylactic failure in clinical fields. As for the gender
difference of VKDB incidence, a nationwide survey in
Japan demonstrated a high incidence of males with VKDB
[13]. Bhanchet et al. reported that the ratio of males to
females was 1.7 for VKDB [14]. Endogenous hormones
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mechanism is unknown.
We observed negative correlations between INR and
gestational age and birth weight. Previous studies
showed a significant relationship between PT and birth
weight as well as gestational age [15]. Our observations
clearly confirmed these findings. The hemostatic system
evolves gradually throughout gestation and early infancy
[16,17]. A previous observation showed that in the healthy
human fetus, both PT and INR decreased gradually
during gestation, which was clearly related to a signifi-
cant increase in coagulation factors including vitamin
K-dependent proteins [18]. In our study, the INR value
decreased during gestation even in term neonates. It is
unknown if the pattern of coagulation system differs
according to the gestational age among term neonates.
This study revealed that there was a wide range of
hematocrit values (37–71%), and we observed a signifi-
cant correlation between INR and hematocrit value. It is
generally thought that the hematocrit level affects the
PT measurement as anemia falsely depresses and polycy-
themia falsely elevates coagulometer readings of INR levels.
The classic PT measured in citrate plasma is influenced by
the hematocrit due to the dilutional effect of plasma
[19,20]. As for INRs determined by CoaguChek XS, there
is no influence of citrate and the clotting time in this
device depends primarily on the concentration of clotting
factors including the endogenous calcium ion concen-
tration in the blood [21]. The hematocrit might also
influence the displayed clotting time by the velocity of
the blood streaming into the reaction zone of the test
strip, or the rate of dissolution of the dried reagents in
the blood, or the concentration of reagent dissolved in
the blood. It is not known if factors influencing blood
viscosity, e.g., fibrinogen, have an effect on the clotting
time measured by the CoaguChek XS. According to the
manufacturer’s report, hematocrit values ranging between
0.25 and 0.55 do not significantly affect the test results.
In our study, hematocrit values were above 0.55 in 27%
of the neonates. Polycythemia is a relatively common
disorder in neonates. The accuracy of CoaguChek INRs in
blood samples with high hematocrit values is an important
issue to study further.
In this study, the CoaguChek XS was operated by four
neonatologists. All study personnel indicated that they
would support the introduction of this device into clinical
practice when they were asked about ease of use. The
failure rate of measuring INRs by the CoaguChek XS
was 2% in our study. A previous study in a pediatric
population demonstrated that failure rates were 2%
with CoaguChek XS and 4% in the laboratory test [22].
One limitation of this study is that CoaguChek XS INR
was measured by a small group of trained neonatologists.
CoaguChek XS has been designed especially for use bynon-health professionals, so anyone can perform the test.
However, if the subject is a neonate, CoaguChek XS INR
measured by less well-trained operators might be less
reliable. The reliability of CoaguChek INR as measured
by a wider group of operators should be verified.
We compared the INR values determined using the
CoaguChek XS POC assay with those obtained using a
standard laboratory assay to assess the accuracy of the
CoaguChek device in neonates. The INR value by Coa-
guChek XS was closely correlated with the laboratory INR
value (r = 0.967). The degree of correlation was the same as
those in other studies performed in adults (r = 0.91–0.95)
[23,24] and children (r = 0.96–0.97) [8,25].
One strength of the present study was a large sample
size compared to previous studies concerned with the
coagulation system that included INR data from a very
small number of neonates. Another strength was that
the sample was composed entirely of healthy individuals,
excluding the study on the accuracy of CoaguChek XS.
This stands in contrast to previous studies, which mostly
included preterm, low birth weight, or morbid neonates.
On the other hand, one limitation of our study is that
we did not compare the INR values, determined with
the CoaguChek device, with other markers of vitamin K
deficiency. The reliability of a coagulation screening test
to detect prophylactic failures might be warranted by
discovering the hemorrhagic tendency of healthy neonates
by chance. Prothrombin time becomes prolonged only
when the prothrombin concentration drops below 50%
of normal [26]. Therefore, while the PT is appropriate
for diagnosis of overt vitamin K deficiency, it might not
be useful for detecting subclinical deficiency. Proteins
induced by vitamin K absence (PIVKA-II) could be
early markers of vitamin K deficiency because they are
detectable before there are alterations in other coagula-
tion tests [27]. Normotest is also used as a marker of
vitamin K deficiency. Infants with VKDB usually display
less than 10% coagulation activity by Normotest, and
apparently healthy infants having less than 20% are
considered to be in a latent hemorrhagic state [13].
However, these markers need to be measured in a central
laboratory. Shortening the delay in obtaining coagulation
test results from a central laboratory is one of the critical
issues to efficiently prevent VKDB. More research by
comparison with PIVKA-II or Normotest is needed before
POC measurement of INR can be recommended for
neonatal care. Another limitation is the time of INR
examination. Because the majority of VKDB infants had
a history of prophylactic vitamin K administration [2],
INR examination at 4 days after birth might be too early
to detect prophylactic failure or incomplete prophylaxis
because INR might still be in the normal range from
recent vitamin K administration. A follow-up test might
be warranted.
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CoaguChek XS appears to be a valid instrument for INR
monitoring even in neonates. In this study, we reported
the RIs (0.90–1.30) for CoaguChek XS INR in healthy
term neonates. In case an INR value exceeds 1.30, fre-
quent (daily or weekly) oral vitamin K administration and
follow-up CoaguChek XS INR evaluations should be
recommended. If prophylaxis is not effective, detailed
investigations (e.g., hemostatic profile tested using venous
access blood samples and liver function test to determine
total and direct bilirubin levels) are required to diagnose
predisposing diseases.
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